Diagnostic markers of cognitive impairments, kits and uses thereof

Abstract

The invention relates to in vitro or ex vivo methods for assessing the cognitive function of a subject in the context of the prevention of neurodegenerative diseases. A particular method comprises a step of associating a subject to a cognitive status selected from healthy cognitive status, Subjective Cognitive Impairment, Mild Cognitive Impairment and neurodegenerative disease, and the association of cognitive status results from the evaluation of glycosylated MCSF and CCR2 expressed at the surface of PBMC in a biological sample from the subject. The present invention also provides kits suitable for implementing such methods.

We claim: 
     
         1 . An in vitro or ex vivo method for assessing the cognitive function of a subject, wherein said method comprises a step of measuring the ratio of glycosylated MCSF over non glycosylated MCSF in a biological sample from the subject, a ratio below 1 being indicative of a AD status, and a ratio above 1 being indicative of a predementia status, said cognitive function being MCI or SCI status. 
     
     
         2 . The method of  claim 1 , wherein said biological sample is from a mammal. 
     
     
         3 . The method of  claim 1 , wherein the biological sample is a fluid biological sample. 
     
     
         4 . The method of  claim 3 , wherein the biological sample is blood, plasma or serum. 
     
     
         5 . The method of  claim 2 , wherein the mammal is a human.